Kodiak Sciences Inc. (NASDAQ:KOD) Stock Position Increased by Two Sigma Investments LP

Two Sigma Investments LP lifted its position in Kodiak Sciences Inc. (NASDAQ:KOD) by 25.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 49,406 shares of the company’s stock after buying an additional 9,941 shares during the period. Two Sigma Investments LP owned approximately 0.09% of Kodiak Sciences worth $492,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. PNC Financial Services Group Inc. raised its position in Kodiak Sciences by 1,501.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock valued at $32,000 after buying an additional 2,988 shares during the period. US Bancorp DE purchased a new position in Kodiak Sciences in the fourth quarter valued at about $40,000. Headlands Technologies LLC purchased a new position in Kodiak Sciences in the fourth quarter valued at about $90,000. Fox Run Management L.L.C. purchased a new position in Kodiak Sciences in the fourth quarter valued at about $118,000. Finally, Jump Financial LLC purchased a new position in Kodiak Sciences in the fourth quarter valued at about $147,000. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

NASDAQ KOD opened at $4.15 on Tuesday. Kodiak Sciences Inc. has a twelve month low of $1.92 and a twelve month high of $11.60. The stock has a market capitalization of $218.97 million, a PE ratio of -1.14 and a beta of 2.27. The stock has a 50-day simple moving average of $3.45 and a 200 day simple moving average of $5.35.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.20). As a group, equities research analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating and set a $3.00 price target on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.